THERAPEUTICS
Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes
In patients with type 2 diabetes, how does rosiglitazone (RGZ) compare with placebo or other drugs for cardiovascular (CV) outcomes?
| The first 150 words of the full text of this article appear below. |
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.
Clinical impact ratings GP/FP/Primary care 
Internal medicine Cardiology 
Endocrine
METHODS
Data sourcesUS Food and Drug Administration (FDA) website; clinical trial registry of the drug manufacturer; and 2 large, recently published trials (Diabetes REduction Assessment with ramipril and rosiglitazone Medication [DREAM] trial and A Diabetes Outcome Prevention Trial [ADOPT]).
Study selection and assessmentrandomised controlled trials (RCTs) that compared RGZ with placebo or other drugs (control) for >24 weeks and reported myocardial infarction (MI) or CV death as outcomes. 42 RCTs (n = 27 847, mean age 56 y) met the selection criteria.
OutcomesMI and CV death.
MAIN RESULTS
Meta-analysis showed that RGZ increased risk of MI more than placebo or other drugs, but groups did not differ for CV death (table).
CONCLUSION
Rosiglitazone increases risk of myocardial infarction and cardiovascular death in patients with
Stanford University School of Medicine, Stanford, California, USA
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
